
    
      Study designed to evaluate safety and tolerability of ARQ 197 in cirrhotic patients with HCC
      who have received â‰¤2 prior systemic regimens for HCC, and whose liver disease severity is
      categorized as Class A and B per Child-Pugh Classification.
    
  